Collaborative Arrangement, Regulatory Milestone Achieved

No definition available.

Name:	cccc_CollaborativeArrangementRegulatoryMilestoneAchieved
Namespace Prefix:	cccc_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Non refundable upfront payment.

+ References

No definition available.

+ Details

Name:	cccc_NonRefundableUpfrontPayment
Namespace Prefix:	cccc_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Number Of Development Candidates

+ References

No definition available.

+ Details

Name:	cccc_NumberOfDevelopmentCandidates
Namespace Prefix:	cccc_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Number of targeted protein degradation.

+ References

No definition available.

+ Details

Name:	cccc_NumberOfTargetedProteinDegradation
Namespace Prefix:	cccc_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Research and development agreement period.

+ References

No definition available.

+ Details

Name:	cccc_ResearchAndDevelopmentAgreementPeriod
Namespace Prefix:	cccc_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Transaction price allocated to performance obligation.

+ References

No definition available.

+ Details

Name:	cccc_TransactionPriceAllocatedToPerformanceObligation
Namespace Prefix:	cccc_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-8

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Cash received from collaborators during the current period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 25
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-25

+ Details

Name:	us-gaap_ProceedsFromCollaborators
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=cccc_BiogenResearchAndLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=cccc_RestatedMerckKGaAAgreementBettaAgreementsAndRocheAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cccc_ResearchAndDevelopmentMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cccc_OneTimeSalesBasedPaymentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaboration and license agreements - Biogen Agreement (Details) $ in Thousands	1 Months Ended			12 Months Ended
	Sep. 30, 2025 USD ($)	Apr. 30, 2024 USD ($)	Feb. 29, 2020 USD ($) protein	Dec. 31, 2025 USD ($)	Dec. 31, 2024 USD ($)	Sep. 30, 2024 developmentCandidate
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue recognized that was included in the contract liability at the beginning of the period				$ 25,930	$ 12,184
Transaction price allocated to performance obligation				23,231
Biogen Research and License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Research agreement, period			54 months
Nonrefundable upfront payment			$ 45,000
Revenue recognized that was included in the contract liability at the beginning of the period	$ 8,000	$ 8,000
Number Of Development Candidates \| developmentCandidate						2
Regulatory milestone achieved	$ 2,000
Calico License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Transaction price allocated to performance obligation				$ 135,100
Maximum \| Biogen Research and License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Number of targeted protein degradation \| protein			5
Maximum \| Biogen Research and License Agreement \| Research and development milestones
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Payment received			$ 35,000
Maximum \| Biogen Research and License Agreement \| One-time sales-based payments
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Payment received			$ 26,000